Key Takeaways

Epitalon is commonly marketed as a sleep, longevity, or "anti-aging" peptide, but the more careful scientific description is that it is an investigational synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), developed from the pineal-peptide and epithalamin research tradition.
The studies below outline its possible roles in telomerase and telomere biology, pineal/circadian signaling, melatonin-related pathways, oxidative-stress biology, and selected aging-related animal models.
That makes Epitalon scientifically interesting, but it does not mean compounded or commercially marketed Epitalon has been proven to improve sleep, slow aging, extend lifespan, or treat disease in humans.
The strongest same-molecule evidence is still mostly cell, animal, and limited exploratory human evidence, and some of the human longevity/survival narrative comes from related pineal extract preparations such as epithalamin rather than Epitalon itself.
‍

[FDA, 2026; Khavinson et al., 2003; Khavinson et al., 2002; Ivko et al., 2021; Khavinson and Morozov, 2003; Korkushko et al., 2006].

‍

Epitalon: an investigational synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Gly, historically linked to the pineal extract epithalamin but not interchangeable with it; canonical aliases include epithalon and AEDG.

By [writer name to confirm]

Overview

The central issue is not that epitalon has no biology. It clearly does. The problem is that biology, small legacy human studies, orphan-designation history, and current peptide-market enthusiasm are repeatedly presented as if they were the same thing as contemporary clinical proof. They are not. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 7-5, with one abstention, to recommend adding both epitalon free base and epitalon acetate to the 503A Bulks List; the recommendation is non-binding, and FDA has not yet taken final action. [FDA, 2026; NCATS, 2025; Financial Times, 2026; RAPS, 2026; Reuters, 2026]

Epitalon is commonly marketed as a sleep, longevity, or "anti-aging" peptide, but the more careful scientific description is that it is an investigational synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), developed from the pineal-peptide and epithalamin research tradition. The studies below outline its possible roles in telomerase and telomere biology, pineal/circadian signaling, melatonin-related pathways, oxidative-stress biology, and selected aging-related animal models. That makes Epitalon scientifically interesting, but it does not mean compounded or commercially marketed Epitalon has been proven to improve sleep, slow aging, extend lifespan, or treat disease in humans. The strongest same-molecule evidence is still mostly cell, animal, and limited exploratory human evidence, and some of the human longevity/survival narrative comes from related pineal extract preparations such as epithalamin rather than Epitalon itself. [FDA, 2026; Khavinson et al., 2003; Khavinson et al., 2002; Ivko et al., 2021; Khavinson and Morozov, 2003; Korkushko et al., 2006]

What it is

Epitalon is a synthetic tetrapeptide with the amino-acid sequence Ala-Glu-Asp-Gly and a molecular formula of C14H22N4O9. FDA's UNII entry lists synonyms including EPITHALON, ALA-GLU-ASP-GLY, and CAS 307297-39-8. NCATS Inxight Drugs lists an aligned structure, molecular weight of about 390.35, and the same InChIKey. [FDA, 2026; NCATS, 2025]

The molecule is commonly described as the putative active short-peptide component derived from work on epithalamin, a bovine pineal-gland peptide preparation. That historical relationship matters, but it does not allow collapse of extract data into synthetic-tetrapeptide efficacy claims. Evidence on epithalamin, synthetic epitalon, and broad "pineal peptides" must be kept separate unless the source studied the same compound, route, and context. FDA's compounding review also treats epitalon free base and epitalon acetate as distinct bulk drug substances and notes that nomination materials were inconsistent about which form was intended. [NCATS, 2025; Khavinson et al., 2002; Khavinson et al., 2003; FDA, 2026]

Material	What it is	Why it cannot be collapsed into "Epitalon"
Epithalamin / epithalamine	Pineal-gland peptide preparation or extract used in older literature	Mixture/extract evidence is not the same as evidence on a single defined tetrapeptide. [Khavinson and Morozov, 2003; Korkushko et al., 2006]
Synthetic epitalon	Defined tetrapeptide Ala-Glu-Asp-Gly	This is the actual molecule of interest in this brief. [FDA, 2026; NCATS, 2025]
"Pineal peptides" as a class	Broader Russian geroprotector literature	Class-level claims do not validate this specific peptide. [Khavinson, 2002; Araj et al., 2025]
Compounded injectable market products	Real-world preparations of variable source/quality	Availability does not prove identity, purity, dose accuracy, or efficacy. [The Guardian, 2026; Reuters, 2026]
Oral/capsule/topical versions	Market forms sometimes discussed online	Route transfer is not justified without route-specific PK/PD and efficacy data. [NCATS, 2025; The Guardian, 2026]

How it's proposed to work

The best-supported mechanistic backbone comes from older cell and tissue work suggesting telomerase activation, telomere elongation, and delayed replicative senescence. In the most widely cited same-molecule paper, epithalon increased telomerase activity and telomere length in human somatic-cell culture. A related paper reported that treated fibroblasts exceeded an expected division limit relative to controls. [Khavinson et al., 2003; Khavinson et al., 2004]

A second mechanistic thread involves chromatin and gene-expression regulation. Older studies reported decondensation of pericentromeric heterochromatin in lymphocyte cultures from older donors, while NCATS summarizes suggested activation of ribosomal genes and release of age-repressed chromosomal regions. [Khavinson et al., 2003; NCATS, 2025]

A third mechanistic thread is oxidative-stress and fibrosis modulation. In retinal pigment epithelial cells exposed to high glucose, epitalon reduced ROS-related injury, improved scratch-wound closure, and modulated antioxidant, EMT, and fibrosis-associated markers. This is still a mechanistic map, not proof of human benefit in diabetic retinopathy or ophthalmic disease. [Gatta et al., 2025]

A newer cell-line study reported telomere-length gains through telomerase upregulation or ALT-associated pathways, reinforcing that epitalon may affect telomere biology in vitro. Again, that is an experimental systems result, not a validated patient outcome. [Al-Dulaimi et al., 2025]

The most defensible mechanistic anchor, then, is that cell and animal studies suggest effects on telomere biology, chromatin state, and oxidative-stress-associated pathways. That is scientifically fair. What is not fair is to translate those findings into "reverses aging," "restores sleep," or "prevents disease" in humans. [Khavinson et al., 2003; Gatta et al., 2025; Araj et al., 2025]

Common forms in circulation

Regulatory databases identify a defined substance named EPITALON/EPITHALON/Ala-Glu-Asp-Gly. FDA's orphan-drug database records a retinitis pigmentosa designation history; NCATS lists an investigational/unapproved posture. [FDA, 2026; NCATS, 2025]

Public reporting in 2026 describes a gray market dominated by injectable and "research use only" peptide vials, with quality problems around identity, purity, and amount. Broader peptide-market journalism describes anti-aging and wellness positioning. These are market behaviors, not validated routes or indications. [Reuters, 2026; The Guardian, 2026; Financial Times, 2026]

Names and aliases

Epitalon; Epithalon; Epithalone; AEDG; Ala-Glu-Asp-Gly; L-alanyl-L-glutamyl-L-aspartyl-glycine; UNII O65P17785G; CAS 307297-39-8. Market adjacency often places it in "longevity" or "anti-aging" peptide discourse alongside MOTS-c, KPV, BPC-157, GHK-Cu, semax, and TB-500, but those pairings are market behavior, not controlled combination evidence. [FDA, 2026; Reuters, 2026; Financial Times, 2026]

Regulatory status

Epitalon is not FDA-approved for any indication. FDA's orphan-drug database shows: generic name Epitalon; date designated September 2, 2010; orphan designation "Treatment of retinitis pigmentosa"; designation status "Designated/Designation Withdrawn or Revoked"; FDA orphan approval status "Not FDA Approved for Orphan Indication." [FDA, 2026]

NCATS Inxight Drugs separately describes epitalon as investigational/unapproved and explicitly states that it has not been approved for therapeutic or prophylactic use by a government health authority in the USA or Europe. [NCATS, 2025]

On U.S. compounding policy, FDA evaluated epitalon free base and epitalon acetate for use in insomnia after the underlying nominations had been withdrawn. FDA staff had recommended against inclusion on the 503A Bulks List, citing inadequate physicochemical characterization, unclear historical compounding use, no evidence supporting effectiveness for insomnia, no clinical safety data supporting human use — particularly by the proposed subcutaneous route — and potential immunogenicity from aggregation and peptide-related impurities. [FDA, 2026]

On July 24, 2026, the Pharmacy Compounding Advisory Committee met to reconsider epitalon free base and acetate for potential inclusion on the 503A Bulks List, evaluating the reviewed use of insomnia. The committee voted 7-5, with one abstention, to recommend adding both epitalon free base and epitalon acetate to the 503A Bulks List — despite FDA staff's own recommendation against inclusion. [FDA, 2026; RAPS, 2026; Reuters, 2026]

The recommendation is advisory only: FDA has not added either substance to the 503A Bulks List, and the vote does not equal FDA approval, does not establish insomnia efficacy, and does not resolve the absence of a contemporary human safety package. [FDA, 2026; RAPS, 2026; Reuters, 2026]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective interventional human study of the same molecule, same route/formulation, with defined outcomes.	Generalized efficacy, route transfer, or disease-treatment claims from weak, small, legacy studies.
Animal model	In vivo rodent or other animal intervention using epitalon.	Claims that epitalon improves humans or prevents aging in patients.
Mechanistic hypothesis	Cell, pathway, chromatin, telomerase, oxidative-stress, EMT/fibrosis, or biomarker work.	"Works by" language implying clinically established human mechanism.
Anecdotal or commercial	Clinic copy, wellness market claims, research-vial pages, influencer discourse.	Proof of safety, efficacy, validated dose, validated route, or regulatory legitimacy.

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support	Source
"Telomere support"	Cell studies reported increased telomerase activity and telomere elongation in some human somatic-cell systems.	It does not support "restores telomeres in patients," "reverses aging," or clinical longevity claims.	[Khavinson et al., 2003; Khavinson et al., 2004; Al-Dulaimi et al., 2025]
"Longevity / anti-aging"	Rat light-regimen work and older geroprotector literature generated aging hypotheses.	It does not support "anti-aging treatment," "life-extension therapy," or "clinically proven longevity peptide."	[Vinogradova et al., 2007; Khavinson, 2002; Financial Times, 2026]
"Insomnia / sleep"	FDA evaluated epitalon free base and acetate for insomnia, and PCAC issued a favorable advisory recommendation. FDA staff, however, identified no studies in patients with insomnia, no clinical sleep-outcome evidence, and no efficacy evidence for the proposed subcutaneous route.	The vote does not establish insomnia efficacy, validated dosing, FDA approval, or current compounding authorization.	[FDA, 2026; RAPS, 2026; Reuters, 2026]
"Eye / retinal support"	Older RP study reported improvement in a treated group; recent in-vitro retinal work showed better wound closure and lower fibrosis/EMT markers.	It does not support "treats retinitis pigmentosa," "improves vision," or "retinal regenerative therapy."	[Khavinson et al., 2002; Gatta et al., 2025; FDA, 2026]
"Cancer prevention"	Some mouse and rat papers reported reduced spontaneous tumor observations under study conditions.	It does not support cancer-prevention claims in humans and should not be framed as oncologically protective.	[Kossoy et al., 2006; Vinogradova et al., 2007; Anisimov and Khavinson, 2009]
"Antioxidant / inflammation control"	Preclinical papers suggest antioxidant effects and reduced stress/fibrosis signaling in specific models.	It does not support "switches off inflammation," "detoxes," or broad systemic clinical claims.	[Kozina et al., 2007; Gatta et al., 2025]
"Immune rejuvenation"	Chicken and aging-model work reported thymic or immune marker changes.	It does not support "boosts immunity" or clinically meaningful immune rejuvenation in patients.	[Pateyk et al., 2013; Lin'kova et al., 2012]
"Safe because short / natural-like peptide"	None. Short peptides can still pose identity, purity, sterility, immunogenicity, and indication-risk problems. FDA identified no clinical safety data supporting human use of epitalon free base or acetate.	It does not support "safe," "low-risk," or "natural therefore harmless." A favorable advisory vote does not close that evidence gap.	[FDA, 2026; Reuters, 2026; The Guardian, 2026]

Key literature

Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. Increased telomerase activity and telomere elongation reported in human somatic-cell culture.

Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. Treated fibroblast cells reportedly exceeded the control division limit.

Vinogradova IA, Bukalev AV, Zabezhinski MA, Semenchenko AV, Khavinson VK, Anisimov VN. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bull Exp Biol Med. 2007;144(6):825-830. Lifespan and tumor observations varied with light regimens and treatment.

Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. Lower spontaneous carcinogenesis observations reported.

Gatta M, Dovizio M, Milillo C, et al. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Rev Rep. 2025;21(6):1822-1834. Improved wound closure; reduced ROS and EMT/fibrosis-related signals against high-glucose injury.

Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. Telomere-length increases reported through telomerase upregulation or ALT-associated activity.

References

U.S. Food and Drug Administration. UNII Search Service entry for EPITALON, UNII O65P17785G. 2026.
U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals: Epitalon; designated 09/02/2010 for treatment of retinitis pigmentosa; designation withdrawn or revoked; not FDA approved for orphan indication. 2026.
U.S. Food and Drug Administration. FDA Briefing Document: Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate) for Inclusion on the 503A Bulk Drug Substances List. May 12, 2026.
NCATS Inxight Drugs. EPITALON substance record O65P17785G. Created/edited March 31, 2025.
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592.
Vinogradova IA, Bukalev AV, Zabezhinski MA, Semenchenko AV, Khavinson VK, Anisimov VN. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine. 2007;144(6):825-830.
Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257.
Korkushko OV, Khavinson VK, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006;142(3):356-359.
Gatta M, Dovizio M, Milillo C, et al. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Reviews and Reports. 2025;21(6):1822-1834.
Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178.
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025;26(6):2691.
Reuters. FDA advisers recommend relaxing U.S. rules on compounding peptides. July 24, 2026.
Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list. July 24, 2026.
The Guardian. FDA to discuss easing restrictions on peptides despite safety concerns. June 26, 2026.
Financial Times. Longevity and "wellness" craze breaks untested drugs out of the lab. 2026.

‍

Epitalon